Natixis Ironwood Pharmaceuticals Inc Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Natixis holds 2 shares of IRWD stock, worth $8. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$8
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding IRWD
# of Institutions
239Shares Held
163MCall Options Held
11.2MPut Options Held
9.1K-
Black Rock Inc. New York, NY22.9MShares$94 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA22MShares$90.6 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT16.4MShares$67.4 Million16.75% of portfolio
-
Pacer Advisors, Inc. Malvern, PA11.3MShares$46.4 Million0.11% of portfolio
-
State Street Corp Boston, MA9.92MShares$40.8 Million0.0% of portfolio
About IRONWOOD PHARMACEUTICALS INC
- Ticker IRWD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 153,231,008
- Market Cap $630M
- Description
- Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...